Aca­cia Phar­ma's twice spurned drug fi­nal­ly makes the FDA cut

Third time’s the charm for Aca­cia Phar­ma.

The Cam­bridge, UK-based com­pa­ny on Thurs­day fi­nal­ly se­cured FDA ap­proval for its treat­ment for pa­tients with post­op­er­a­tive nau­sea …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER